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Abstract
Background: Angiotensin-converting enzyme inhibitors and the angiotensin-receptor blocker valsartan ameliorate
ventricular remodeling after myocardial infarction (MI). Based on previous clinical trials, a maximum clinical dose is
recommended in practical guidelines. Yet, has not been clearly demonstrated whether the recommended dose is
more efficacious compared to the lower dose that is commonly used in clinical practice.
Method/Design: Valsartan in post-MI remodeling (VALID) is a randomized, open-label, single-blinded multicenter
study designed to compare the efficacy of different clinical dose of valsartan on the post-MI ventricular
remodeling. This study also aims to assess neurohormone change and clinical parameters of patients during the
post-infarct period. A total of 1116 patients with left ventricular dysfunction following the first episode of acute ST-
elevation MI are to be enrolled and randomized to a maximal tolerable dose (up to 320 mg/day) or usual dose (80
mg/day) of valsartan for 12 months in 2:1 ratio. Echocardiographic analysis for quantifying post-MI ventricular
remodeling is to be conducted in central core laboratory. Clinical assessment and laboratory test are performed at
fixed times.
Discussion: VALID is a multicenter collaborative study to evaluate the impact of dose of valsartan on the post-MI
ventricular remodeling. The results of the study provide information about optimal dosing of the drug in the
management of patients after MI. The results will be available by 2012.
Trial registration: NCT01340326
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Background
Progressive enlargement of the heart chamber and dete-
rioration of contractile function after myocardial infarc-
tion (MI), termed post-MI ventricular remodeling, is
associated with development of heart failure and poor
prognosis [1-3]. The magnitude of post-MI remodeling
is influenced by several determinants, most notably
infarct size [4], but also by ventricular wall stress [5],
patency of infarct-related artery [6], and a number of
neurohormonal factors [7]. Thus, the consequence of
post-MI remodeling varies among patients with acute
MI even in the era of reperfusion therapy [8]. Modifica-
tion of neurohormonal acitivities, particularly the
rennin-angiotensin-aldosterone system (RAAS), can sig-
nificantly influence the process of ventricular remodel-
ing after acute MI. Suppression of angiotensin activity
either by inhibition of angiotensin-converting enzyme
(ACE) [9-11] or by blockade of angiotensin II receptor
[12] attenuates ventricular dilatation and improves clini-
cal outcomes. Based on the results from major pivotal
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guidelines that the maximal clinical dose of ACE inhibi-
tors used in those trials be given to patients after acute
MI [13,14]. A seminal finding that the neurohormone
level is linearly related with mortality [15] in patients
with heart failure also suggests the potential benefit of
higher doses.
However, the optimal level of RAAS antagonism in the
treatment of heart failure or post-MI remodeling is still a
matter of debate. Although administration of higher dose
of angiotensin-converting enzyme (ACE) inhibitor was
more beneficial than lower dose in animal model of post-
MI remodeling [16], results of clinical studies were not
confirmatory. In the VALIANT study [17], addition of
ARB valsartan to ACE inhibitor resulted in similar degree
of post-MI left ventricular (LV) remodeling compared to
either drug alone, although in the Val-HeFT study [18],
LV remodeling in heart failure was more favorable in the
combination therapy group. In several clinical studies that
directly compared different doses of ACE inhibitors in
patients with chronic heart failure, the results of clinical
outcomes as well as neurohormonal responses were incon-
sistent, and sometimes irrelevant because of the impracti-
cal dosing of drugs chosen for the comparison. In the
ATLAS study [19], patients receiving high-dose lisinopril
(32.5-35.0 mg/day) had a nonsignificant (8%) lower risk of
death and a significant (12%) lower rate of death and hos-
pitalization compared with patients receiving low-dose lisi-
nopril (2.5-5.0 mg/day). The CHIPS trial [20] compared
low-dose (50 mg/day) with high-dose (100 mg/day) capto-
pril therapy and demonstrated a nonsignificant trend
toward less worsening heart failure and hospitalization in
the high-dose group. In the NETWORK trial [21], there
was no difference in the primary endpoint of combined
death, heart failure-related hospitalization, and worsening
of heart failure among the three groups of low dose (5
mg/day), medium dose (10 mg/day), and high dose (20
mg/day) enalapril therapy. Furthermore, the lower dose
used in NETWORK (enalapril 5 mg/day) [21] was too
small, and the higher dose used in ATLAS (lisinopril 35
mg/day) [19] was excessive for practical use. The recent
publication of the Heart failure Endpoint evaluation of
Angiotensin Antagonist Losartan trial (HEAAL) presented
notable evidence of the superiority of 150 mg/day of losar-
tan versus 50 mg per day on the primary outcomes of
death or hospitalization in patients with systolic heart fail-
ure [22]. However, the study subjects were limited to
patients who were intolerant to ACE inhibitors [22], pre-
cluding extrapolation of the result to general patients.
Furthermore, the optimal dosing of ARB agents has not
been explored in the population of post-MI. Thus, the
question of whether submaximal dose of ARB, which are
lower than those in major pivotal trials but typically used
in clinical practice, can offer similar benefit in post-MI
ventricular remodeling remains to be solved. This is more
so in the Asian population, wherein moderate dose ARB
has been shown to provide sufficient protection from car-
diovascular risk [23]. Therefore, the primary objective of
the VALsartan in post-mI remoDeling (VALID) study is
to address this issue in Korean patients who suffered their
first acute ST-elevation MI by comparing the impact of
different doses of valsartan, an ARB demonstrated as effec-
tive as ACE inhibitor in post-MI patients [12], on echocar-
diographic variables of left ventricular remodeling during
the follow-up period of 1 year. The comparison dose of
valsartan will be 80 mg per day, as commonly prescribed
after MI in Korea, versus 320 mg per day, a targeted dose
in major clinical trials [12,24].
Trial objectives
The primary hypothesis to be tested is whether high
dose valsartan significantly reduces ventricular remodel-
ing as measured by echocardiography in post-MI
patients during a 12-month follow-up period, compared
with the usual dose of control group.
Methods and Design
Study design
VALID is a prospective, multicenter, randomized, open-
label, active controlled study with two parallel study
groups. VALID is being conducted in 18 tertiary hospi-
tals throughout South Korea. Participants are randomly
allocated into the usual dose group and high dose group
and followed-up for 12 months after discharge. Overall
study algorithm is depicted in Figure 1. Baseline echo-
cardiographic examination and neurohormonal assay are
performed before discharge. Study approval was given
by the institutional review board at each participating
center, and consecutive, eligible patients are provided
written informed consent.
Randomization
Randomization will take place following initial echocar-
diographic estimation of left ventricular ejection frac-
tion, which is conducted after stabilization by
reperfusion therapy or conservative treatment. Eligible
patients are randomly assigned in a 1:2 ratio to receive
the usual dose (valsartan 80 mg/day) or a high dose
(valsartan up to 320 mg/day). Random allocation with
stratified technique is generated automatically by a cen-
tralized web based tool (http://www.cnrres.co.kr/valid)
so it cannot be influenced by researchers.
Approval
This study follows the Helsinki Declaration’sp r i n c i p l e s ,
meaning that all patients sign a written informed con-
sent stating that participation is voluntary and that par-
ticipation can
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quences concerning their current or future medical
treatment. This study protocol was approved by the
institutional review board of Dong-A University hospital
and each participating center.
Patient population
Men and women aged 18 years or older who suffer their
first acute ST-elevation myocardial infarction with the
sign of LV dysfunction are eligible for this study (Table
1). In the present study, LV dysfunction is defined as an
ejection fraction < 50% using a modified Simpson’sr u l e
[25]. Enrollment criteria are intended to include patients
in acute stage of infarction, within 10 days of symptom
onset, who are typically treated under modern therapeu-
tic strategy. Patients are recruited regardless of whether
they received reperfusion therapy, either thrombolysis or
primary percutaneous coronary intervention, or not.
Pharmacological therapy other than study drug, includ-
ing beta-adrenergic blockers, is allowed according to the
discretion of attending physician. Patients who have
contraindication to the study drug or major concomitant
disease are excluded (Table 1).
Intervention and comparator descriptions
Eligible patients are randomly assigned in a 1:2 fashion
to either the usual dose group (valsartan 80 mg/day) or
the high dose group (valsartan up to 320 mg/day). In
the usual dose group, valsartan 40 mg twice a day is
administrated throughout the study period. For those in
the high dose group, dose is up-titrated to 80 mg twice
a day before hospital discharge and finally to 160 mg
twice a day after 2 weeks during outpatient visits. The
process of the trial conduct is illustrated in Figure 2. If
up-titration is not clinically feasible, either because of
Eligible Patients
1. First STEMI
2. Ejection fraction < 50%
Randomization
(n=1116) 1:2
Valsartan
40 mg bid
Valsartan
160 mg bid
Primary endpoint : LV remodeling by Echo
1 year
Titrate to
Target doses
Figure 1 Overall study algorithm of the VALID study. This figure
illustrates the study algorithm. A total of 1116 patients will be
randomly allocated into the usual dose group (n = 372) and high
dose group (n = 744) and followed-up for 12 months after
discharge.
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
Subjects > 18 years of age Contraindication for use of ARB
Either gender Urgent need for revascularization procedure
First episode of acute MI Severe heart failure (NYHA IV or need for inotropic support)
Typical pain lasting ≥ 20 minutes Persistent (>1 hour) severe hypotension (systolic blood pressure < 90
mmHg)
ST elevation of more than 1 mm in at least 2 separate leads on the
ECG
Refractory or potentially lethal arrhythmias
An echocardiographic LV EF < 50% Hemodynamically significant right ventricular infarction
Optimal recording of echocardiographic imaging of apical chamber
views
Congenital heart disease
Patients who provide written informed consent Primary valvular disease, severer than mild degree
Idiopathic hypertrophic cardiomyopathy
Concomitant inflammatory cardiomyopathy
Significant renal dysfunction (serum creatinine 2.5 mg/dl)
Significant hepatic dysfunction (serum transaminase more than 3 times
normal)
Anemia (hemoglobin < 10 mg/mL or 6 mmol/L)
Psychiatric disorders, alcohol or drug abuse
Life expectancy is less than 1 year
Participation in any other pharmacological study within 2 months
Refusal or inability to provide informal consent
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administered subsequently as maximal tolerable dose.
Outcomes measurement
The primary outcome of the study is the changes of the
echocardiographic indices of LV remodeling, which is
the LV volume index at end-systolic and end-diastolic
time as measured by modified Simpson’sr u l e[ 2 5 ] ,d u r -
ing the study period. Echocardiographic records from
participating institute are sent to the core echocardio-
graphy laboratory for the analysis. Secondary outcomes
include occurrence of predefined clinical events (all-
cause death, cardiovascular death, hospitalization, revas-
cularization), changes of plasma level of neurohormone
(B-type natriuretic peptide, norepinephrine, aldosterone),
and echocardiographic indices other than ventricular
volume (ejection fraction, wall motion score index,
mitral inflow, tissue Doppler index) at 12 months (Table
2). Neurohormone measurement will be conducted in a
core laboratory.
Follow-up protocol
During the study period, study visits are scheduled at
week -2 (high-dose group only), and 1, 3, 6, 9, 12
months. At each visit, patients undergo a complete phy-
sical examination, medical history-taking, and assess-
ment of drug compliance. Investigators evaluate all
clinical and laboratory adverse events at each visit. To
monitor safety, serum creatinine and urea nitrogen con-
centrations are determined at every study visit. New
York Heart Association (NYHA) functional class [26]
and predefined clinical events are recorded at each clini-
cal visit. Echocardiographic examination and neurohor-
monal assay are performed at 3 and 12 months after
discharge. After a routine review with 50% of the
patients enrolled, early cessation of the trial will be
decided by the institutional review board and study
sponsor when the trial appears to be futility or causing
unexpected harm to participants.
Adverse effects
Analysis of safety related data is performed with respect
to frequency of serious adverse events, stratified by
causality and intensity of morbidity in both treatment
groups.
Patients are interviewed at each visit about the occur-
rence of any adverse events, including the time of onset,
duration, and severity; all information is recorded on a
case report from. The causal relation to the study drug
and the intensity of adverse events are evaluated by the
investigators. Serious adverse events (SAE) have to be
reported to the institutional review board and study
sponsor by the principal investigator within 24 hours
after the SAE becomes known.
Withdrawals
Patients are free to withdraw trial participation at their
own request at any time and without giving reasons for
their decision. Moreover, the primary investigator can
withdraw study patients, if continuation of the trial
would be detrimental to the patient’s
well being. Withdrawals will be documented in the case
report form and in the patient’s medical records and all
ongoing severe adverse event have to be followed up.
In-hospital period Post-discharge follow-up
Discharge
160mg bid
High-dose
group
40mg bid
40mg bid
Usual-dose 
group
Visit 1 
2weeks
Visit 2 
4weeks
80mg bid
Figure 2 Titration scheme of study drug. In the usual dose
group, valsartan 40 mg twice a day is administrated throughout the
study period. For those in the high dose group, dose is up-titrated
to 80 mg twice a day before hospital discharge and finally to 160
mg twice a day after 2 weeks during outpatient visits.
Table 2 Study Objectives
Primary Objective Secondary objectives
Change in the LV index measured
by echocardiography from
baseline to follow-up
Change in functional capacity
(NYHA class)
All cause mortality
Cardiovascular death
Hospitalization
Revascularization procedures
(emergency and elective)
Change in B-type natriuretic
peptide (BNP) level
Change in plasma norepinephrine
level
Change in serum aldosterone level
Change in ejection fraction
Change in MI index (wall motion
score index)
Change in sphericity index
Change in mitral inflow index
(mitral E/A ratio, mitral deceleration
time)
Change in tissue Doppler index
(mitral Ea)
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The sample size calculation is based on the primary out-
come and the primary analysis for the intention-to-treat
population. In the VALIANT Echo study, [17] a sample
size of 600 patients was determined necessary to detect,
with a 90% power, a 7.6 mL difference in end-diastolic
volume between the treatment groups. Because the pre-
sent study enrolls more patients with mild degree (EF <
50%) LV dysfunction, we anticipate that the difference
of ventricular volume between treatment groups will be
smaller than the previous study. Thus, detection of 3.8
mL difference, with a two-sided level of significance a =
5% and a power of 1-b = 90%, in end-diastolic volume
between treatment groups would require a sample size
of 279 patients in a usual dose of valsartan group and
558 patients in a high dose valsartan group. Assuming
25% of patients are lost to follow-up or with missing
data, as reported in the GISSI-3 study [27], the required
sample size of this study will be a total of 1,116 patients.
The study is likely to be underpowered in terms of
assessing secondary outcomes if this size is employed.
Variability data for the outcome measures could be used
to inform design a subsequent larger-scale randomized
controlled trial, if post hoc analysis reveals this study to
be underpowered.
Statistical analyses
A consultant group of statisticians has been appointed
to conduct the statistical work for this study, including
data completion, interim analysis, application of statisti-
cal technique and final assessment. The principal analy-
sis will be an intention-to-treatment basis. For baseline
characteristics, continuous variables are assessed using
the Student t test and discrete variables are compared
using the chi-square test. The two-sided null-hypothesis
for the primary outcome measure states that usual and
high dose valsartan lead to the same expected change of
ventricular remodeling during the 12 months after MI.
This null-hypothesis will be tested by application of an
analysis of covariance that adjusts for age, gender, and
cardiovascular risk factors. Primary outcome will be
compared using 2-sample t tests. Event-free cumulative
survival rates are plotted using the Kaplan-Meier
method and comparisons are made between patients
with and those without clinical events using the log-
rank test. A Cox proportional hazards model with the
use of forward selection based on the likelihood ratio
test will be implemented for multivariate analysis to
determine which prognostic factors identified in the uni-
variate analysis were significantly related to 12-month
clinical events. Assessments for the change of neurohor-
mone and other echocardiographic indices will be com-
pared between treatment groups at 12-month follow-up
using 2-sample t tests.
We will compare proportions of missing data using
chi-square tests and agreement between data collection
methods using Lin’s Concordance Correlation Coeffi-
cient. Additionally, sensitivity analyses will be conducted
using different patient populations (per protocol popula-
tion excluding patients with relevant protocol viola-
tions), different imputation techniques for missing
values, and different statistical methods for taking into
account covariates. A value of p < 0.05 will be consid-
ered statistically significant.
Discussion
Despite the accepted roles of ACE inhibitors and the
ARB agent valsartan in the treatment of post-MI LV
dysfunction [9-12], the appropriate dose remains
unclear. Although clinical guidelines recommend to pre-
scribe the doses that have been shown to reduce the
risk of cardiovascular events in clinical trials [13,14], it
is common practice for the patients to be maintained on
doses appropriate for initiation of therapy rather than
doses up-titrated to target doses used in the clinical
trials. Concerns about patient’s intolerance to higher
doses might be an attributable factor for such practice.
Although the recent HEAAL study demonstrated a
superiority of higher dose over low dose losartan in
ACE intolerant patients with heart failure, the evidence
is still lacking for the setting of post-MI LV dysfunction
and for general population. The VALID study has been
designed to address the issue of optimal dosing of ARB
v a l s a r t a ni nt h ep o s t - M Ip a t i e n t sb yc o m p a r i n gt h e
major echocardiographic outcome of post-MI LV remo-
deling, which is the LV volume index. Because the dif-
ferences of clinical outcomes between high- versus low-
dose therapy is expected to be considerably smaller than
those of placebo-controlled landmark trials, quantitative
measurement of post-MI ventricular remodeling can be
a reasonable surrogate endpoint.
Conclusions
The enrollment criteria for the VALID is different from
those of other major post-MI ACE inhibitor trials in
that patients with milder systolic LV dysfunction (EF
<50%) is eligible for VALID while more severe form of
LV dysfunction (EF <35% or clinical sign of heart fail-
ure) was required for enrollment in previous major clin-
ical trials [9-12]. Two factors have been considered
when deciding the cut-off value for LV dysfunction.
First, the majority of patients referred to the participat-
ing hospital receive reperfusion therapy in Korea [28],
leading to substantial increment of the number of the
patients with more preserved LV contractile function.
Second, as the proportion of elderly population among
the patients with acute MI is increasing, the pattern of
post-MI remodeling may exhibit a different picture.
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commonly than younger patients, even after smaller size
acute MI. In the PREAMI study [29], ACE inhibitor (8
mg/day of perindopril) could reduce progressive LV
remodeling in elderly patients who had a relatively pre-
served LV function with EF ≥40%. Thus, the increasing
proportion of elderly population in acute MI cases in
Korea [30] can make it feasible to examine the effect of
ARB agent on post-MI remodeling in the presence of
moderate LV dysfunction for the VALID study.
List of abbreviations
ACE: Angiotensin-converting enzyme; MI: Myocardial infarction; LV: Left
ventricle; EF: Ejection fraction; RAAS: Renin-angiotensin-aldosterone system;
VALID: Valsartan in post-myocardial infarction remodeling; βAR: Beta-
adrenergic blocker; ARB: Angiotensin II receptor blocker.
Acknowledgements
This study was financially supported by Novartis Korea, Seoul, Korea. As this
is an investigator-initiated trial, the authors designed and conducted the
study. Data collection has been managed by an independent clinical
research center. The funding body does not interfere in the analysis and
interpretation of the data. We would like to thank all members of present
study group for their ideas, suggestions, participation and support.
Author details
1Department of Internal Medicine, Dong-A University College of Medicine,
Busan, Korea.
2Department of Cardiovascular Center, Dong-A University
Hospital, Busan, Korea.
3Department of Internal Medicine, Daegu Catholic
University College of Medicine, Daegu, Korea.
4Department of Internal
Medicine, Pusan National University College of Medicine, Busan, Korea.
5Department of Internal Medicine, Inje University College of Medicine, Pusan
Paik Hospital, Busan, Korea.
6Department of Internal Medicine, Gyeongsang
National University College of Medicine, Jinju, Korea.
7Department of Internal
Medicine, Yeungnam University College of Medicine, Daegu, Korea.
8Department of Internal Medicine, Keimyung University College of Medicine,
Deagu, Korea.
9Department of Internal Medicine, Ulsan University College of
Medicine, Ulsan, Korea.
Authors’ contributions
YDK is the Principle Investigator for the study, contributed to the study
design and to drafting and revising the manuscript. YRC made significant
contribution to concept of the study, drafting and reviewing manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 May 2011 Accepted: 22 November 2011
Published: 22 November 2011
References
1. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial
infarction. Experimental observation and clinical implications. Circulation
1990, 81:1161-1172.
2. Gaudron P, Ellis C, Kugler I, Ertl G: Progressive left ventricular dysfunction
and remodeling after myocardial infarction: potential mechanisms and
early predictors. Circulation 1993, 87:755-763.
3. St John Sutton M, Pfeffer MA, Plapoert T: for the SAVE Investigators.
Quantitative two-dimensional echocardiographic measurements are
major predictor of adverse cardiovascular events after myocardial
infarction. Circulation 1994, 89:68-75.
4. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA,
Braunwald E: Myocardial infarction size and ventricular function in rats.
Circ Res 1979, 44:503-512.
5. Hammerman H, Kloner RA, Alker KJ, Schoen FJ, Braunwald E: Effect of
transient increased afterload during experimentally induced acute
myocardial infarction in dogs. Am J Cardiol 1985, 55:566-570.
6. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AE, Braunwald E: Effect of
captopril on progressive ventricular dilatation after anterior myocardial
infarction. N Eng J Med 1988, 11:12-19.
7. Noda K, Sasaguri M, Ishida M, Ikeda M, Arakawa K: Role of locally formed
angiotensin II and bradykinin in the reduction of myocardial infarct size
in dogs. Cardiovas Res 1993, 27:334-340.
8. Giannuzzi P, Temporelli PG, Bosimini E Gentile F, Lucci D, Maggioni AP,
Tavazzi L, Badano L, Stoian I, Piazza R, Heyman I, Levantesi G, Cervesato E,
Geraci E, Nicolosi GL: Heterogeneity of left ventricular remodeling after
acute myocardial infarction: results of the Gruppo Italiano per lo Studio
della Sopravvivenze nell’Infarto Miocardico-3 Echo substudy. Am Heart J
2001, 141:131-138.
9. Pfeffer MA, Braunwald E, Moye LA: on the behalf of the SAVE
Investigators. Effect of captopril of mortality and morbidity in patients
with left ventricular dysfunction after myocardial infarction: results of
the Survival and Ventricular Enlargement Trial. N Engl J Med 1992,
327:685-691.
10. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of
ramipril on mortality and morbidity of survivors of acute myocardial
infarction with clinical evidence of heart failure. Lancet 1993, 342:821-828.
11. Kober L, Torp-Pederson C, Carlsen E, Bagger H, Eliasen P, Lyngborg K,
Videbaek J, Cole DS, Auclert L, Pauly NC: A clinical trial of the angiotensin-
converting-enzyme inhibitor trandopril in patients with left ventricular
dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation
(TRACE) Study Group. N Engl J Med 1995, 233:1670-1676.
12. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP,
Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M,
Edward S, Zelenkofske S, Sellers MA, Califf RM: For the Valsartan in Acute
Myocardial Infarction Trial Investigators. Valsartan, captopril or both in
myocardial infarction complicated by heart failure, left ventricular
dysfunction or both. N Engl J Med 2003, 349:1893-1906.
13. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG,
Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA,
Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD,
Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK,
Nishimura R, Ornato JP, Page RL, Riegel B, American College of Cardiology;
American Heart Association Task Force on Practice Guidelines; American
College of Chest Physicians; International Society for Heart and Lung
Transplantation; Heart Rhythm Society: ACC/AHA 2005 Guideline Update
for the Diagnosis and Management of Chronic Heart Failure in the
Adult: a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Writing Committee to
Update the 2001 Guidelines for the Evaluation and Management of
Heart Failure): developed in collaboration with the American College of
Chest Physicians and the International Society for Heart and Lung
Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005,
112:e154-e235.
14. Krum H: The Task Force for the diagnosis and treatment of CHF of the
European Society of Cardiology. Guidelines for the diagnosis and
treatment of chronic heart failure: full text (update 2005). Eur Heart J
2005, 26:1115-1140.
15. Francis GS, Cohn JN, Jonson G Rector TS, Goldman S, Simon A: Plasma
norepinephrine, plasma renin acitivity, and congestive heart failure.
Relation to survival and the effect of therapy in V-HeFT II. The V-HeFT
VA Cooperative Study Group. Circulation 1993, 87(6 Suppl):VI40-VI48.
16. Yang Y, Zhang P, Song L Ruan Y, Xu X, Li Y, Zhou Y, Tian Y, Xu Y, Chen Z:
Comparision of the doses of enalapril in preventing left ventricular
remodeling after acute myocardial infarction in the rat. China Med J
2002, 115:347-351.
17. Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK,
Warnica W, Khrakovskaya M, Arnold MO, Schwarz Y, Velazquez EJ, Califf RM,
McMurray JV, Pfeffer MA: Changes in ventricular size and function in
patients treated with valsartan, captopril or both after myocardial
infarction. Circulation 2005, 111:3411-3419.
18. Wong M, Staszewsky L, Latini R, Bariera S, Volpi A, Chiang YT, Benza RL,
Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN: Val-HeFT
Heart Failure Trial Investigators. Valsartan benefits left venricular
Cho et al. Trials 2011, 12:247
http://www.trialsjournal.com/content/12/1/247
Page 6 of 7structure and function in heart failure; Val-Heft echocardiographic study.
J Am Coll Cardiol 2002, 40:970-974.
19. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD,
Massie BM, Lyden L, Thygesen K, Uretsky BF: Comparative effect of low
and high doses of the angiotension-converting enzyme inhibitor,
lisinopril, on mortality and morbidity in chronic heart failure. Circulation
1999, 100:2312-2318.
20. Clement DL, De Buyzere M, Tomas M, Vanavermaete G: Long-term effects
of clinical outcome with low and high dose in the Captopril in Heart
Insufficient Patients Study (CHIPS). Acta Cardiol 2000, 55:1-7.
21. The NETWORK Investigators: Clinical outcome with enalapril in
symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998,
19:481-489.
22. HEAAL Investigators: Effects of high-dose versus low-dose losartan on
clinical outcomes in patients with heart failure (HEAAL study): a
randomized, double-blind trial. Lancet 2009, 374:1840-1848.
23. Jikei Heart Study group: Valsartan in a Japanese population with
hypertension and other cardiovascular disease (Jikei Heart Study): a
randomized, open-label, blinded endpoint morbidity-mortality study.
Lancet 2007, 369:1431-1439.
24. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor
blocker valsartan in chronic heart failure. N Engl J Med 2001,
345:1667-1675.
25. Lang RM, Bierig M, Devereux RB, flachskampf FA, Foster E, Pellikka PA,
Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT,
Sutton MS, Stewart WJ: American Society of Echocardiography’s
Guidelines and Standards Committee: European Association of
Echocardiography. J Am Soc Echocardiogr 2005, 18:1440-1463.
26. The Criteria Committee of the New York Heart Association: Nomenclature
and Criteria for Diagnosis. Boston, Little Brown;, 9 1994.
27. Nicolosi GL, Latini R, Marino P, Maggioni AP, Barlera S, Franzosi MG,
Geraci E, Santoro L, Tavazzi L, Toqnoni G, Vecchio C, Volpi A: The
prognostic value of predischarge quantitative two-dimensional
echocardiographic measurenets and the effects of early lisinopril
treatment on left ventricular structure and function after acute
myocardial infarction in the GISSI-3 Trial. Eur Heart J 1996, 17:1646-1656.
28. Lee KH, Jeong MH, Ahn YK, Kim JH, Chae SC, Kim YJ, Hur SH, Seong IW,
Hong TJ, Choi DH, Cho MC, Kim CJ, Seung KB, Chung WS, Jang YS, Cho JG,
Park SJ: Sex differences of the clinical characteristics and early
management in the Korea Acute Myocardial Infarction Registry. Korean
Circulation J 2007, 37:64-71.
29. The PREAMI Investigators: Effect of angiotensin-converting enzyme
inhibition with perindopril on left ventricular remodeling and clinical
outcome. Results of the Randomized Perindopril and Remodeling in
Elderly with Acute Myocardial Infarction (PREAMI) study. Arch Intern Med
2006, 166:659-666.
30. Moon HK, Kim YD, Yang DG, Kim SG, Cha KS, Kim MH, Kim JS, Cha TJ,
Joo SJ, Lee JW, Hong TJ, Shin YW, Kim DI, Kim DS, Park JS, Shin DG, Kim YJ:
Age and Gender Distribution of patients with acute myocardial
infarction admitted to university hospitals during the period of 1990-
1999. Korean Circulaiton J 2003, 33:92-96.
doi:10.1186/1745-6215-12-247
Cite this article as: Cho et al.: The impact of dose of the angiotensin-
receptor blocker valsartan on the post-myocardial infarction ventricular
remodeling: study protocol for a randomized controlled trial. Trials 2011
12:247.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cho et al. Trials 2011, 12:247
http://www.trialsjournal.com/content/12/1/247
Page 7 of 7